Posted on 08/09/2009 in Pharmaceutical Company Product News Archimedes - a pharmaceutical firm with bases in several European countries - has revealed that it has filed an application with the Food and Drug Administration (FDA) for its NasalFent treatment.
The application for NasalFent, which is a differentiated fentanyl nasal spray for the rapid relief of breakthrough cancer pain, was filed on August 31st.
Additionally, a marketing authorisation application is currently being reviewed for the treatment by the European Medicines Evaluation Agency.
"This year has been fundamental in building momentum around NasalFent," explained Richard de Souza, chief executive officer of Archimedes.
He added: "Earlier in the year we reported exciting clinical results that demonstrate NasalFent's clear advantages over existing competitor treatments, either on the market or in development."
Archimedes has offices in Germany, the UK, France and Ireland and its core products include Gliadel, Zomorph, Pabrinex and Zibor.
It states that NasalFent, which has undergone a successful phase III trail, could be ready for manufacture in 2010.
Other news stories from 08/09/2009
Read more in the Zenopa News Archive
How this news is generated
|
